Biomea Fusion
Company Details
Status: Public
Employees: 101-250
Location:
Redwood City, California, United States of America
Type:
sample
Technology:
sample
About: We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response.
Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Biomea Fusion | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.